American Society of Clinical Oncology

ASCO 2021

This program was supported by Bayer Inc.

virtual-conference

prostate cancer conference highlights

AUDIO & VIDEO CAPSULES

Moderated by Dr. Ricardo Rendon

This conference is available through our podcast

Abstract Summaries

Dr. Steven Yip

  • Abstract LBA4: Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).
ASCO-GU 2021
ASCO-GU 2021
Dr. Steven Yip
/
Rate this summary:

Watch video capsule

Abstract Summaries

Dr. Michael Ong

  • Abstract 5000: A phase 3 trial with a 2×2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novometastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
  • Abstract 5002: Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.
ASCO-GU 2021
ASCO-GU 2021
Dr. Michael Ong
/

Watch video capsule

Abstract Summaries

Dr. Claudio Jeldres

  • Abstract 5072: Real-world first-line treatment patterns in patients with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database.
ASCO-GU 2021
ASCO-GU 2021
Dr. Claudio Jeldres
/

Watch video capsule

Abstract Summaries

Dr. Lucia Nappi

  • Abstract 5020: Concordance of DNA damage repair (DDR) gene mutations in paired primary and metastatic prostate cancer (PC) samples.
ASCO-GU 2021
ASCO-GU 2021
Dr. Lucia Nappi
/

Watch video capsule

Abstract Summaries

Dr. Anupam Batra

  • Abstract 5046: ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).
ASCO-GU 2021
ASCO-GU 2021
Dr. Anupam Batra
/

Watch video capsule

The opinions expressed in these audio capsules are those of the physicians.